Tumors with tumor microenvironment type I (TMTI-I), such as those with high PD-L1 expression and the presence of CD8 + TILs, are more likely to respond positively to anti-PD-1/PD-L1 therapy. This evidence concerns the gene CD8A and neoplasm.